Table 1. Percentage of mice with microscopic preneoplastic and/or neoplastic liver lesions in each group*.
| Group (number of mice) | Mice with neoplasia | Total mice with hepatic preneoplasia (AHF and LFCA) and neoplasia | ||
|---|---|---|---|---|
| Mice with HCA only | Mice with HCC only | Total mice with HCA and HCC | ||
| WT female (n = 4) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| HT female (n = 3) | 1 (33.33%) | 0 (0%) | 1 (33.33%) | 1 (33.33%) |
| WT female Hp (n = 4) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| HT female Hp (n = 9) | 0 (0%) | 2 (22.22%) | 2 (22.22%) | 3 (33.33%) |
| WT male (n = 2) | 0 (0%) | 1 (50%) | 1 (50%) | 1 (50%) |
| HT male (n = 6) | 2 (33.33%) | 0 (0%) | 2 (33.33%) | 5 (83.33%) |
| WT male Hp (n = 6) | 2 (33.33%) | 1 (16.66%) | 3 (50%) | 4 (66.66%) |
| HT male Hp (n = 10) | 0 (0%) | 4 (40%) | 4 (40%) | 7 (70%) |
*
No statistically significant differences were observed between the groups analyzed within each column. WT, wild-type; HT, hepatitis C virus transgenic. Preneoplasia includes altered hepatocellular foci (AHF) and large foci of cellular alteration (LFCA); Neoplasia includes hepatocellular adenoma (HCA) and hepatocellular carcinoma (HCC).